Mirrors of Medicine
@mirrorsofmedicine.bsky.social
Open, multidisciplinary platform facilitating access to unique #CME programmes w/ focus on improving clinical decision making. Both online & offline.
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
March 7, 2025 at 1:25 PM
The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
aacrjournals.org/cancerdiscov...
The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing.
#ProstateCancer
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
February 25, 2025 at 11:29 AM
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
aacrjournals.org/clincancerre...
findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
OS analysis of Young-PEARL out on Lancet Oncology:
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic #BreastCancer
www.sciencedirect.com/science/arti...
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic #BreastCancer
www.sciencedirect.com/science/arti...
February 24, 2025 at 9:23 AM
OS analysis of Young-PEARL out on Lancet Oncology:
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic #BreastCancer
www.sciencedirect.com/science/arti...
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic #BreastCancer
www.sciencedirect.com/science/arti...